Document is current

Any future updates will be listed below

Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post-hoc analysis of the DAPA-BODY trial

Crossref DOI link: https://doi.org/10.1038/s41440-026-02572-1

Published Online: 2026-02-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark